Hybrid cells for treating cancer patients
View Patent ↗The present invention relates to cancer treatment compositions and methods for treating a specific cancer patient population. In particular, the application describes methods of treating a patient with cancer, such as a neuroblastoma, with a hybrid cell preparation.
1. A composition comprising a hybrid cell preparation, wherein the hybrid cell preparation is prepared by a method comprising:
(a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker,
(b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker,
(c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion,
(d) obtaining a resultant hybrid cell population stained with both the first and second markers, and
(e) purifying the resultant hybrid cell population;
wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after said contacting.
2. The composition of claim 1 , wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting.
3. The composition of claim 1 , wherein less than 10% of the resultant hybrid cell population is reactant cells.
4. The composition of claim 1 , wherein less than 5% of the resultant hybrid cell population is reactant cells.
5. The composition of claim 1 , further comprising a pharmaceutically acceptable vehicle.
6. The composition of claim 2 , wherein the first and second fluorescent dyes are endotoxin-free, pyrogen-free or both.
7. The composition of claim 1 , wherein the neoplastic cell is a tumor cell.
8. The composition of claim 7 , wherein the tumor cell is a primary tumor cell.
9. A method of treating cancer, comprising:
(i) providing a hybrid cell preparation prepared by a method comprising:
(a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker,
(b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker,
(c) contacting said neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion,
(d) obtaining a resultant hybrid cell population stained with both the first and second markers, and
(d) purifying the resultant hybrid cell population;
wherein the method does not involve antibiotic or metabolic selection, said purifying is accomplished in less than about 24 to 48 hours after the contacting;
(ii) resuspending the resultant hybrid cell preparation in a pharmaceutically acceptable vehicle, and
(iii) administering the hybrid cell preparation to a cancer patient.
10. The method of claim 9 , wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting.
11. A cancer vaccine comprising a hybrid cell preparation and a pharmaceutically acceptable vehicle, wherein the hybrid cell preparation is prepared by a method comprising:
(a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker,
(b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker,
(c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion,
(d) obtaining a resultant hybrid cell population stained with both the first and second markers,
(e) purifying the resultant hybrid cell population, and
(f) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle;
wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after the contacting.
12. The cancer vaccine of claim 11 , wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting.
13. The cancer vaccine of claim 11 , wherein the pharmaceutically acceptable vehicle is saline.
14. A tumor vaccine comprising a hybrid cell preparation and a pharmaceutically acceptable vehicle, wherein the hybrid cell preparation is prepared by a method comprising:
(a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first marker,
(b) staining a dendritic cell population with a second marker, wherein the first marker is different from the second marker,
(c) contacting the neoplastic cell population and the dendritic cell population with one another under conditions that promote cell fusion,
(d) obtaining a resultant hybrid cell population stained with both the first and second markers,
(e) purifying the resultant hybrid cell population, and
(f) resuspending the resultant hybrid cell population in a pharmaceutically acceptable vehicle;
wherein the method does not involve antibiotic or metabolic selection, the purifying is accomplished in less than about 24 to 48 hours after the contacting.
15. The tumor vaccine of claim 14 , wherein the first marker is a fluorescent dye, the second marker is a fluorescent dye, and the resultant hybrid cell population is purified by fluorescence activated cell sorting.
16. The tumor vaccine of claim 14 , wherein the pharmaceutically acceptable vehicle is saline.
17. A kit comprising
(i) at least two dyes that are essentially endotoxin-free or pyrogen-free or both; and
(ii) instructions for preparing hybrid cells from reactant cells by a method comprising:
(a) staining a neoplastic cell population freshly isolated from a patient without culturing with a first dye from the at least two dyes,
(b) staining a dendritic cell population with a second dye from the at least two dyes, wherein said first dye is different from said second dye,
(c) contacting said neoplastic cell population and said dendritic cell population with one another under conditions that promote cell fusion,
(d) obtaining a resultant hybrid cell population stained with both the first and second dyes, and
(e) purifying the resultant hybrid cell population;
wherein said method does not involve antibiotic or metabolic selection, said purifying is accomplished in less than about 24 to 48 hours after said contacting.